Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
